Search results
Results from the WOW.Com Content Network
Ezetimibe works by decreasing cholesterol absorption in the intestines. [5] Ezetimibe was approved for medical use in the United States in 2002. [4] It is available as a generic medication. [5] In 2022, it was the 79th most commonly prescribed medication in the United States, with more than 8 million prescriptions. [11] [12]
Ezetimibe/rosuvastatin, sold under the brand name Ridutrin among others, is a combination medication used to treat high cholesterol. [6] [7] In some countries it is sold as a kit or a pack containing two distinct pills. [8] [9] The combination was approved for medical use in the United States in March 2021. [4]
Bempedoic acid/ezetimibe, sold under the brand name Nexlizet among others, is a fixed-dose combination medication used for the treatment of high cholesterol. [ 1 ] [ 3 ] It is a combination of bempedoic acid and ezetimibe .
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
A few facts for you according to the folks from The Anxiety and Depression Association of America and the National Institute of Mental Health: In 2020, an estimated 14.8 million U.S. adults aged ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [22] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries. [24]
Managing cholesterol at the site of absorption is an increasingly popular strategy in the treatment of hypercholesterolemia [citation needed].Cholesterol absorption inhibitors are known to have a synergistic effect when combined a class of antihyperlipidemics called statins, to achieve an overall serum cholesterol target.